Cargando…

Targeting the ubiquitin‐proteasome system in a pancreatic cancer subtype with hyperactive MYC

The myelocytomatosis oncogene (MYC) is an important driver in a subtype of pancreatic ductal adenocarcinoma (PDAC). However, MYC remains a challenging therapeutic target; therefore, identifying druggable synthetic lethal interactions in MYC‐active PDAC may lead to novel precise therapies. First, to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lankes, Katharina, Hassan, Zonera, Doffo, María Josefina, Schneeweis, Christian, Lier, Svenja, Öllinger, Rupert, Rad, Roland, Krämer, Oliver H., Keller, Ulrich, Saur, Dieter, Reichert, Maximilian, Schneider, Günter, Wirth, Matthias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7718946/ https://www.ncbi.nlm.nih.gov/pubmed/33099868 http://dx.doi.org/10.1002/1878-0261.12835

Ejemplares similares

Indirect targeting of MYC sensitizes pancreatic cancer cells to mechanistic target of rapamycin (mTOR) inhibition
por: Schneeweis, Christian, et al.
Publicado: (2022)

AP1/Fra1 confers resistance to MAPK cascade inhibition in pancreatic cancer
por: Schneeweis, Christian, et al.
Publicado: (2022)

Rationale for MYC imaging and targeting in pancreatic cancer
por: Schneider, Günter, et al.
Publicado: (2021)

Kras(G12D) induces EGFR-MYC cross signaling in murine primary pancreatic ductal epithelial cells
por: Diersch, Sandra, et al.
Publicado: (2015)

Epigenetic drug screening defines a PRMT5 inhibitor–sensitive pancreatic cancer subtype
por: Orben, Felix, et al.
Publicado: (2022)

HDAC2 Facilitates Pancreatic Cancer Metastasis
por: Krauß, Lukas, et al.
Publicado: (2022)

MYC and EGR1 synergize to trigger tumor cell death by controlling NOXA and BIM transcription upon treatment with the proteasome inhibitor bortezomib
por: Wirth, Matthias, et al.
Publicado: (2014)

MTOR inhibitor-based combination therapies for pancreatic cancer
por: Hassan, Zonera, et al.
Publicado: (2018)

The SUMO pathway in pancreatic cancer: insights and inhibition
por: Schneeweis, Christian, et al.
Publicado: (2020)

Targeting the MYC Ubiquitination-Proteasome Degradation Pathway for Cancer Therapy
por: Sun, Xiao-Xin, et al.
Publicado: (2021)

SUMO pathway inhibition targets an aggressive pancreatic cancer subtype
por: Biederstädt, Alexander, et al.
Publicado: (2020)

The OTUD6B‐LIN28B‐MYC axis determines the proliferative state in multiple myeloma
por: Paulmann, Carmen, et al.
Publicado: (2022)

The ubiquitin-proteasome pathway in cancer.
por: Spataro, V., et al.
Publicado: (1998)

The ubiquitin proteasome system in neuropathology
por: Lehman, Norman L.
Publicado: (2009)

The recognition of ubiquitinated proteins by the proteasome
por: Grice, Guinevere L., et al.
Publicado: (2016)

Immuno- and Constitutive Proteasomes Do Not Differ in Their Abilities to Degrade Ubiquitinated Proteins
por: Nathan, James A., et al.
Publicado: (2013)

The Ubiquitin Conjugating Enzyme: An Important Ubiquitin Transfer Platform in Ubiquitin-Proteasome System
por: Liu, Weigang, et al.
Publicado: (2020)

Poxvirus Exploitation of the Ubiquitin-Proteasome System
por: Barry, Michele, et al.
Publicado: (2010)

The Ubiquitin-Proteasome Pathway in Huntington's Disease
por: Mitra, Siddhartha, et al.
Publicado: (2008)

Enzymatic Blockade of the Ubiquitin-Proteasome Pathway
por: Ernst, Robert, et al.
Publicado: (2011)

The ubiquitin-proteasome system in Alzheimer's disease
por: Oddo, Salvatore
Publicado: (2008)

Autoregulation of the 26S proteasome by in situ ubiquitination
por: Jacobson, Andrew D., et al.
Publicado: (2014)

Ubiquitin Proteasome System in Stress and Disease
por: Karpov, Dmitry, et al.
Publicado: (2012)

Intracellular Dynamics of the Ubiquitin-Proteasome-System
por: Chowdhury, Maisha, et al.
Publicado: (2015)

Ubiquitin-Proteasome System in Neurodegenerative Disorders
por: Rao, Geeta, et al.
Publicado: (2015)

The Ubiquitin–Proteasome System in Immune Cells
por: Çetin, Gonca, et al.
Publicado: (2021)

Ubiquitin-proteasome system in diabetic retinopathy
por: Svikle, Zane, et al.
Publicado: (2022)

Copper homeostasis and the ubiquitin proteasome system
por: Zhang, Bichao, et al.
Publicado: (2023)

The Ubiquitin–Proteasome System in Tumor Metabolism
por: Wang, Jie, et al.
Publicado: (2023)

Writing and erasing MYC ubiquitination and SUMOylation
por: Chen, Yingxiao, et al.
Publicado: (2019)

The role of the ubiquitination-proteasome pathway in breast cancer: Applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer
por: Orlowski, Robert Z, et al.
Publicado: (2003)

Polypharmacology of small molecules targeting the ubiquitin–proteasome and ubiquitin-like systems
por: Amelio, Ivano, et al.
Publicado: (2015)

Interplay between the Ubiquitin Proteasome System and Ubiquitin-Mediated Autophagy in Plants
por: Su, Tong, et al.
Publicado: (2020)

Ubiquitin-like protein conjugation and the ubiquitin–proteasome system as drug targets
por: Bedford, Lynn, et al.
Publicado: (2010)

Ubiquitin Engineering for Interrogating the Ubiquitin–Proteasome System and Novel Therapeutic Strategies
por: Tang, Jason Q., et al.
Publicado: (2023)

The ubiquitin-like modifier FAT10 is degraded by the 20S proteasome in vitro but not in cellulo
por: Oliveri, Franziska, et al.
Publicado: (2023)

The ubiquitin–proteasome system in spongiform degenerative disorders
por: Whatley, Brandi R., et al.
Publicado: (2008)

Role of the ubiquitin proteasome system in Alzheimer's disease
por: Upadhya, Sudarshan C, et al.
Publicado: (2007)

Role of the ubiquitin proteasome system in Parkinson's disease
por: Lim, Kah-Leong, et al.
Publicado: (2007)

The ubiquitin-proteasome system regulates chloroplast biogenesis
por: Huang, Weihua, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_k32ond8vqncnfm7q8fmvmd1cs8